SENSE BIOPHARMA AS

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Organization

CEO: MD
Mariann Dønnum1969
Chairman of the board: DØ
Dag Øivind Dvergsten1959
Years since formation: 19 years; since Jan 17, 2005
Type: Limited company
VAT registered: No
Number of employees: 0

Ownership

Number of shares and share classes: 80,630; 1 share class
Total number of shareholders: 17; 7 companies, 10 persons

Financials

Annual total result 2020: -10,437,161; NOK
Total equity 2020: -2,726,672; NOK

Last update: Aug 29, 2024

Management

Management / administration

Name	Role	Shares
MD Mariann Dønnum 1969 Resigned	Managing Director/CEO	-

Board

Name	Role	Shares
DØ Dag Øivind Dvergsten 1959	Chairman	-
JM Jon Morten Melhus 1956	Board Member	-
SL Stephen Lewis Minger 1955	Board Member	-
CV Camila Vicencio Esguerra 1969 Resigned	Board Member	-

Others

Name	Role	Shares
B BDO AS	Auditor	-

Top 10 individual shareholders

Name	Role	Shares
ØD Øivind Grouff Dvergsten 2002	-	37.41 % directly
PL Per Leif Saxegaard 1959	-	8.68 % directly
TK Trond Riiber Knudsen 1964	-	4.64 % indirectly
SG Siri Leine Granlie 1962	-	1.45 % indirectly
AG Arnstein Granlie 1957	-	1.45 % indirectly
OZ Olav Dalen Zahl 1961	-	1.16 % indirectly
PA Pål Andreas Dvergsten 1953	-	1.16 % directly

Last update: Oct 2, 2023

Ownership

Company shareholders

Name	Share class	Number of shares	Share
ØD Øivind Grouff Dvergsten 2002	Ordinary shares	30,166	37.41 %
PL Per Leif Saxegaard 1959	Ordinary shares	7,000	8.68 %
T TRK GROUP AS	Ordinary shares	3,739	4.64 %
G GRANCO AS	Ordinary shares	2,337	2.9 %
S SYNDIN AS	Ordinary shares	1,168	1.45 %
F FJORDSYN AS	Ordinary shares	934	1.16 %
PA Pål Andreas Dvergsten 1953	Ordinary shares	934	1.16 %
S SNØTINDENE AS	Ordinary shares	934	1.16 %
AK Arne Klungland 1963	Ordinary shares	600	0.74 %
XW Xiaofeng Wang 1982	Ordinary shares	467	0.58 %
M MELHUS COMMUNICATION AS	Ordinary shares	467	0.58 %
PS Peter Skorpil 1975	Ordinary shares	467	0.58 %
X XITS AS	Ordinary shares	467	0.58 %
JO Jens Olav Jacobsen 1953	Ordinary shares	467	0.58 %
AC Anne Cecilie Berg Beckmann 1962	Ordinary shares	117	0.15 %
EB Eshrat Babaie 1949	Ordinary shares	100	0.12 %
MW Merete Thune Wiiger 1964	Ordinary shares	100	0.12 %

Last update: Apr 4, 2024

Financials

in NOK

Summary

Year	2020
Total operating income	0
Annual Total Result	-10,437,161
Total assets	440,401
Total liabilities	3,167,073
Total equity	-2,726,672

P&L

Year	2020
Total operating income	0
Total operating costs	10,304,471
Operating result	-10,304,471
Financial income/costs	-132,690
Profit before tax	-10,437,161
Total tax & extraordinary income/cost	0
Annual Total Result	-10,437,161

Balance overview

Year	2020
Total fixed assets	11,993
Total current assets	428,408
Total assets	440,401
Short term debt	3,167,073
Long term debt	0
Total liabilities	3,167,073
Contributed capital	13,643,355
Retained earnings	-16,370,026
Total equity	-2,726,672
Total equity and liabilities	440,401

SENSE BIOPHARMA AS987 700 378